Overview:

Summary

The industry analysis specialist’s new report, “Glaucoma – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global glaucoma market. The report identifies the key trends shaping and driving the global glaucoma market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global glaucoma sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the global glaucoma market. Its Scope includes:
- Annualized global glaucoma therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include Calcium agonists, Rho kinase inhibitors and various combination therapies. In addition to this, RNA-interference, Non-Specific Endothelin-A Receptor Blockers and Adenosine HA3-antagonists are also being studied for the possible use in glaucoma patients.
- Analysis of the current and future market competition in the global glaucoma therapeutics market. Key market players covered include Merck and Santen Pharmaceuticals, NicOx and Bausch and Lomb
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with glaucoma.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global glaucoma market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global glaucoma market landscape? – Identify, understand and capitalize.

Companies Mentioned

NicOx SA and Bausch and Lomb
Novagali Pharma SA
Merck (MSD) and Santen Pharmaceuticals, Japan

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Glaucoma: Market Characterization 5
2.1 Overview 5
2.2 Glaucoma Market Size 5
2.3 Glaucoma Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Glaucoma Market 7
2.4.1 Drivers of the Glaucoma Market 7
2.4.2 Barriers for the Glaucoma Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Glaucoma Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.2.1 Xalatan 11
3.2.2 Cosopt 12
3.2.3 Alphagan P 14
3.2.4 Travatan Z 14
3.2.5 Lumigan 15
3.3 Key Takeaway 17
4 Glaucoma: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 Glaucoma Therapeutics – Promising Drugs under Clinical Development. 20
4.4 Drugs under Clinical Development 20
4.4.1 Tafluprost (Saflutan) 20
4.4.2 NCX-116 (Formerly PF-03187207) 21
4.4.3 Catioprost 22
4.5 Glaucoma Therapeutics Market – Clinical Pipeline by Mechanism of Action 22
4.6 Glaucoma Pipeline – Pipeline by Phase of Clinical Development 23
4.6.1 Glaucoma Therapeutics – Phase III Clinical Pipeline 24
4.6.2 Glaucoma Therapeutics – Phase II Clinical Pipeline 24
4.6.3 Glaucoma Therapeutics – Phase I Clinical Pipeline 25
4.6.4 Glaucoma Therapeutics – Preclinical Pipeline 26
4.6.5 Glaucoma Therapeutics – Discovery Pipeline 26
4.7 Discontinued / Suspended Drugs for Glaucoma 26
4.8 Key Takeaway 27
5 Glaucoma Market: Implications for Future Market Competition 28
6 Glaucoma Market: Future Players in the Glaucoma Market 29
6.1 Introduction 29
6.2 NicOx SA and Bausch and Lomb 29
6.2.1 Overview 29
6.2.2 Business Description 30
6.2.3 Ophthalmology Portfolio 30
6.2.4 Glaucoma Product Portfolio 30
6.3 Novagali Pharma SA 31
6.3.1 Overview 31
6.3.2 Business Description 31
6.3.3 Glaucoma Product Portfolio 32
6.4 Merck (MSD) and Santen Pharmaceuticals, Japan 32
6.4.1 Overview 32
6.4.2 Business Description 33
6.4.3 Glaucoma Product Portfolio 34
7 Glaucoma Market: Appendix 36
7.1 Definitions 36
7.2 Acronyms 36
7.3 Research Methodology 36
7.3.1 Coverage 37
7.3.2 Secondary Research 37
7.3.3 Forecasting 38
7.3.4 Primary Research 41
7.3.5 Expert Panels 41
7.4 Contact Us 41
7.5 Disclaimer 41
7.6 Sources 42

1.1 List of Tables
Table 1: Global Glaucoma Market Revenues, ($bn) 2001-2009 6
Table 2: Global Glaucoma Market Forecast, ($bn) 2009-2016 7
Table 3: Strategic Competitor Assessment of the Major Marketed Products in Glaucoma, 2010 11
Table 4: Major Marketed Products in the Glaucoma Market, 2010 17
Table 5: Glaucoma Therapeutics –Promising Drugs Under Clinical Development, 2010 20
Table 6: Glaucoma Therapeutics – Phase III Clinical Pipeline, 2010 24
Table 7: Glaucoma Therapeutics – Phase II Clinical Pipeline, 2010 24
Table 8: Glaucoma Therapeutics – Phase I Clinical Pipeline, 2010 25
Table 9: Glaucoma Therapeutics – Preclinical Pipeline, 2010 26
Table 10: Glaucoma Therapeutics – Preclinical Pipeline, 2010 26
Table 11: List of Discontinued Drugs for Glaucoma, 2010 26
Table 12: NicOx: Glaucoma Pipeline, 2010 30
Table 13: Novagali Pharma SA –Glaucoma and Ophthalmology Pipeline, 2010 31
Table 14: Merck and Santen Pharmaceuticals - Ophthalmology Pipeline, 2010 34
Table 15: Santen Pharmaceuticals - Ophthalmology Pipeline, 2010 34
Table 16: Santen Pharmaceuticals – Glaucoma Pipeline, 2010 34

1.2 List of Figures
Figure 1: Global Glaucoma Market Revenues, ($bn) 2001–2009 6
Figure 2: Global Glaucoma Market Forecast, ($bn) 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Glaucoma Market, 2010 9
Figure 4: Reduction in IOP in Patients Using Either Latanoprost or Cosopt over Three Months 13
Figure 5: Technology Trends Analytic Framework of the Glaucoma Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of Glaucoma Pipeline – Description, 2010 19
Figure 7: Glaucoma Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Glaucoma Pipeline by Phase of Clinical Development, 2010 23
Figure 9: Implications for Future Market Competition in the Glaucoma Market, 2010 28
Figure 10: Glaucoma Therapeutics Market – Clinical Pipeline by Company, 2010 29
Figure 11: GlobalData Methodology, 2010 37
Figure 12: GlobalData Market Forecasting Model, 2010 40